Seed raise exceeding 200% of target positions the DebitMyData Digital Identity LLM (DID-LLM) for Global Partnerships and Licensing FORT LAUDERDALE, Fla., July 30, 2025 (GLOBE NEWSWIRE) — DebitMyData™, Inc.—the powerhouse has closed a seed round at more than twice its original target. This surge of investor confidence paves the way
Freiburg (Germany), Suzhou (China) and Boston (USA), July 30, 2025: Dr. Falk Pharma GmbH and Allianthera (Suzhou) Biopharmaceuticals Co., Ltd. Announce Strategic Partnership to Develop a Novel AhR Agonist for the Treatment of Moderate to Severe Ulcerative Colitis Dr. Falk Pharma GmbH, a research-based pharmaceutical company specializing in digestive and
Ambiq Announces Pricing of Initial Public Offering AUSTIN, Texas, July 29, 2025 (GLOBE NEWSWIRE) — Ambiq Micro, Inc. (“Ambiq”), a technology leader in ultra-low-power semiconductor solutions for edge AI, today announced the pricing of its upsized initial public offering of 4,000,000 shares of its common stock at a public offering
REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), July 29, 2025, 10:45 pm CET / 4:45 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH)
Nyxoah to Release Second Quarter 2025 Financial Results on August 18, 2025 Mont-Saint-Guibert, Belgium – Tuesday July 29, 2025, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the
Seed raise exceeding 200% of target positions the DebitMyData Digital Identity LLM (DID-LLM) for Global Partnerships and Licensing DebitMyData Logo FORT LAUDERDALE, Fla., July 30, 2025 (GLOBE NEWSWIRE) — DebitMyData, Inc.—the powerhouse has closed a seed round at more than twice its original target. This surge of investor confidence paves
Freiburg (Germany), Suzhou (China) and Boston (USA), July 30, 2025: Dr. Falk Pharma GmbH and Allianthera (Suzhou) Biopharmaceuticals Co., Ltd. Announce Strategic Partnership to Develop a Novel AhR Agonist for the Treatment of Moderate to Severe Ulcerative Colitis Dr. Falk Pharma GmbH, a research-based pharmaceutical company specializing in digestive and
Ambiq Announces Pricing of Initial Public Offering Ambiq Announces Pricing of Initial Public Offering AUSTIN, Texas, July 29, 2025 (GLOBE NEWSWIRE) — Ambiq Micro, Inc. (“Ambiq”), a technology leader in ultra-low-power semiconductor solutions for edge AI, today announced the pricing of its upsized initial public offering of 4,000,000 shares of